Tronox: Price Increases in a Downturn Are Still a Downturn
Three straight quarters of rising TiO2 prices, 36% EBITDA growth — and a Q4 guide that goes backwards. The stock peaked on the last earnings call and has fallen 62% since.
TROX · Earnings Call · 2026-11-05
Tronox: Price Increases in a Downturn Are Still a Downturn
The anomaly John Romano keeps pointing at
John Romano has run this business for a long time, and he knows that what happened in the third quarter is not supposed to happen. TiO2 pricing rose 3% sequentially in Q1, 5% in Q2, and 4% in Q3 — inside a market where volumes were falling and Europe was described as softer than we anticipated. He put it plainly on the call:
I'll age myself here, four decades of doing this, you never typically have price going up when the market is weak. That never comes out in the same sentence. This has a lot to do with this shift in the supply dynamic that's going on.
That supply dynamic argument is not a new line — it has been the spine of this equity story for four straight quarters, and it is now the number-three keyword in the company's own keyword stack. It is also, on the face of it, delivering: revenue of $827 million, up 18%, TiO2 revenue up 19% on 10% more volume and 9% better price/mix, zircon revenue up 58%, and adjusted EBITDA of $101 million at a 12.2% margin, up 36% year-over-year.
Except Q4 guidance is $80 million to $90 million — a step down of 11% to 21% sequentially despite the fact that pricing is expected to hold and zircon prices are guided up mid-single digits. Full-year free cash flow, which was going to be positive, is now a use of $25 million to $50 million. That gap between the top line and the bottom line is the whole story.
What the price increases actually bought
The CFO's bridge is the most useful page in the deck: roughly $100 million of higher raw materials year-over-year, $60 million to $90 million from deliberately slowing the mines, $18 million of extended outages at Stallingborough and the SR kiln, and about $100 million of FX. Against that sits the cost program — more than $175 million of run-rate savings by year-end, above the high end of the original target. Both things are true at once, and the arithmetic nets to an operating loss.
Gross margin of 6.3% is the lowest in the ten-year record barring the 2025Q4 collapse, and operating income of negative $67 million in the June quarter tells you the pricing victory is not reaching the bottom of the P&L. The most telling evidence for the cost program being real is not the headline number — it is that fixed-cost absorption and idle charges were only $9 million in Q3 versus the $25 million to $30 million per quarter this company ate in the last downturn.
What has genuinely escalated is the input stack. raw material is now the company's single highest-ranked keyword, ahead of everything else management discusses, with natural gas second and Sulfuric acid sixth. Romano is blunt that price will not close the gap: “We have announced additional price increases in Europe to help recover a portion of those costs, but we do not expect pricing alone to fully offset the higher cost environment.” — John Romano, Chief Executive Officer · 2026-11-05 The Q4 headwind — $15 million to $20 million — is concentrated at two sites, Stallingborough and Bahia, where UK natural gas runs at roughly ten times the US price. That is a war-duration bet, not a self-help story.
The moat is, increasingly, a customs order
Strip away the chemistry and a large share of Tronox's pricing power is now trade policy. Anti-dumping duties have been reinstated in India; the UK has preliminarily recommended duties at 48%, the high end of the range; Japan has opened its own investigation; and the EU anti-absorption case should land midway through the first half of 2027. Romano notes only Canada and Mexico are left without a live action. This maps neatly onto a global theme: trade defense mechanisms ranked in the market's top-25 keywords this quarter, a rare cross-market echo for a $417 million market-cap chemical company.
But a duty is a moat with a map attached. The obvious risk — raised directly by Alembic's Hassan Ahmed — is that Chinese exporters simply redirect tonnage to the shrinking set of undefended markets. Romano concedes the mixture: “There was a fair amount of inventory that was built. Anytime duties are stayed, there is a significant move.” — John Romano, Chief Executive Officer · 2026-11-05 India, Tronox's second-largest country, will not show a volume benefit until the channel digests that pre-buying, which pushes the benefit into late Q1 2027 at the earliest.
Rare earths: the 2031 option nobody is paying for
The genuinely new item this quarter is JX Advanced Metals. The two companies will jointly fund roughly $32 million on a 50/50 basis to complete a definitive feasibility study on a proposed cracking and leaching facility in Australia and a pre-feasibility study on a US refinery, targeting up to 10,000 tonnes per year of total rare earth oxides. The timeline, read aloud on the call, is bracing: DFS by end-2027, construction from mid-to-late 2028, completion late 2030, US refining late 2031. Romano is honest about the payoff: “It's too early to put a number on the profitability of this opportunity, and the feasibility work will help us define that.” — John Romano, Chief Executive Officer · 2026-11-05
Strategic optionality is real here — this is a company with mineral separation chemistry and heavy rare earths in its tailings, and Western governments are funding exactly this. But it cannot appear in a 2027 EBITDA line, and the company is simultaneously cutting capital expenditure by $30 million to about $230 million, some of which the CFO concedes is deferral rather than elimination.
The tape has already voted
The most striking fact about this report is not in the transcript at all. Tronox's stock peaked at $6.95 on August 6, 2026 — the exact day of the prior earnings call, the one where Romano said “we're in a comfortable place, and we think we're on the right trajectory with 2 quarters of price improvement under our belt in a market that has not been supported by demand improvement.” — John Romano, Chief Executive Officer · 2026-08-06 It has since fallen 62.4%, and is down 59.5% over 90 days, to a $417 million market cap.
The market is making a specific judgment: that a price-led recovery in a declining-volume market, funded by a $3.1 billion net debt stack, is a margin transfer from equity to customers and creditors rather than an earnings recovery. The fundamentals support the skepticism — effective net cash of negative $2.9 billion, interest coverage of negative 1.2x, and liquidity down to $509 million from $674 million at the start of the year.
And there is a quieter tell in the language. In February 2026 Romano said the company was “not banking on a significant recovery” — John D. Romano, Chief Executive Officer · 2026-02-19. Nine months later, the Q4 outlook repeats the same disclaimer. Meanwhile he offers the industry observation that “many companies are not making money. I would say most are not.” — John Romano, Chief Executive Officer · 2026-11-05 A recovery that is never assumed in guidance, in the fourth consecutive quarter of being promised, is a recovery the market has stopped pricing.
The bull case now reduces to two things: the war ends and sulfur, natural gas and diesel roll over (Romano says sulfur purchases already lined up for next year look cheaper), and India plus Middle East duty-driven share gains convert into volume in the first half of 2027. The bear case is that both of those are other people's decisions. For a company at 6% gross margins with negative interest coverage, that is an uncomfortable place to wait.